Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue (2018 - 2025)

Bicycle Therapeutics' Non-Current Deffered Revenue history spans 8 years, with the latest figure at $35.5 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 61.18% year-over-year to $35.5 million; the TTM value through Dec 2025 reached $35.5 million, down 61.18%, while the annual FY2025 figure was $35.5 million, 61.18% down from the prior year.
  • Non-Current Deffered Revenue reached $35.5 million in Q4 2025 per BCYC's latest filing, down from $74.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $115.1 million in Q2 2023 to a low of $25.3 million in Q2 2021.
  • Average Non-Current Deffered Revenue over 5 years is $69.9 million, with a median of $78.2 million recorded in 2025.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 165.87% in 2023, then plummeted 61.18% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $52.1 million in 2021, then dropped by 20.38% to $41.5 million in 2022, then surged by 165.87% to $110.2 million in 2023, then dropped by 17.01% to $91.5 million in 2024, then crashed by 61.18% to $35.5 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Non-Current Deffered Revenue are $35.5 million (Q4 2025), $74.1 million (Q3 2025), and $82.9 million (Q2 2025).